GeneDx CEO acquires 3,404 company shares

GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock.

Accepted by SEC EDGAR 03/09/2026 - 07:54 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock. On March 6, 2026, she obtained 3,404 shares of GeneDx Class A common stock directly from the company in an exempt transaction at $88.11 per share, based on that day’s closing price.

Following this acquisition, Stueland directly holds 42,087 shares of GeneDx Class A common stock. The transaction was executed under a Subscription Agreement between GeneDx and Stueland and was structured to qualify for exemption under Rule 16b-3(d).

Insider Trade Summary

Grant/Award: 3,404 shares

Grant/Award 1 txn

Insider Stueland Katherine

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	3,404	$88.11	$300K

Holdings After Transaction: Class A Common Stock — 42,087 shares (Direct)

Footnotes (1)

1. F1. Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GeneDx (WGS) disclose for Katherine Stueland?

GeneDx disclosed that CEO Katherine Stueland acquired 3,404 shares of its Class A common stock. The shares were obtained directly from the company in an exempt transaction under Rule 16b-3(d) pursuant to a Subscription Agreement executed on March 6, 2026.

At what price did Katherine Stueland acquire GeneDx (WGS) shares?

Katherine Stueland acquired 3,404 GeneDx Class A common shares at a price of $88.11 per share. This price matched the closing price of GeneDx’s Class A common stock on March 6, 2026, as specified in the Subscription Agreement with the company.

How many GeneDx (WGS) shares does Katherine Stueland own after this transaction?

After acquiring 3,404 additional shares, Katherine Stueland directly holds 42,087 shares of GeneDx Class A common stock. This updated total reflects her direct ownership immediately following the March 6, 2026 exempt acquisition from GeneDx Holdings Corp.

What was the structure of Katherine Stueland’s GeneDx (WGS) share acquisition?

The acquisition was made directly from GeneDx under a Subscription Agreement dated March 6, 2026. Stueland acquired 3,404 Class A common shares in an exempt transaction pursuant to Rule 16b-3(d), at the stock’s closing market price of $88.11 per share on that date.

Was Katherine Stueland’s GeneDx (WGS) share acquisition an exempt transaction?

Yes. The filing states that Katherine Stueland acquired 3,404 GeneDx Class A common shares in an exempt transaction. It was conducted pursuant to Rule 16b-3(d) under a Subscription Agreement with GeneDx, using the March 6, 2026 closing price of $88.11 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stueland Katherine

(Last) (First) (Middle)

C/O GENEDX HOLDINGS CORP.

333 LUDLOW ST., NORTH TOWER, 6TH FLOOR

(Street)

STAMFORD CT 06902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	03/06/2026		A		3,404	A	$88.11	42,087	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.

	/s/ Bridget Brown, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.